# Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study

> **NCT01025505** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 40 (actual)

## Conditions studied

- Treatment
- Stem Cell Transplantation

## Interventions

- **DRUG:** Nilotinib
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT01025505
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-12
- **Final completion:** 2020-09-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01025505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01025505, "Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01025505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*